Voyager Therapeutics Logo.jpg
Neurocrine Biosciences and Voyager Therapeutics Form Strategic Development and Commercialization Collaboration for Parkinson’s Disease and Friedreich’s Ataxia Collaboration leverages strengths and efforts of both companies towards developing and commercializing life-changing treatments for severe neurological diseases Neurocrine Biosciences gains...
Voyager Therapeutics Logo.jpg
Voyager Therapeutics Announces Positive Longer-Term Data for VY-AADC for Parkinson’s Disease
November 07, 2018 16:10 ET | Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
Figure 1
Voyager Therapeutics Announces Longer-Term Data from Ongoing Phase 1b Trial of VY-AADC for Advanced Parkinson’s Disease
March 09, 2018 07:02 ET | Voyager Therapeutics, Inc.
Robust and durable improvements in patients' motor function achieved with substantial reductions in use of daily oral levodopa and other Parkinson’s disease medications; one-time administrations of...